Not FDA-approved1,2,4Evidence: Limited human dataHormones · Sexual and reproductive health

Kisspeptin-101

Key takeaway

Kisspeptin-10 is a lab-made peptide of ten amino acids, one of a family of kisspeptin peptides that act on reproductive-hormone signalling in the brain. It is not an FDA-approved drug, and FDA reports that no product containing it is approved in any country.1 FDA’s 2024 evaluation found only small, short studies in about 300 people, and insufficient evidence to judge whether it works for low testosterone caused by the brain or pituitary (secondary hypogonadism) in men.1 FDA’s advisory committee voted 11 to 0 against adding it to the list of substances pharmacies may use in compounding. Kisspeptin-10 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6

Kisspeptin-10 at a glance

What it isA synthetic ten-amino-acid peptide that activates the kisspeptin receptor (GPR54), which is concentrated in the hypothalamus, according to FDA’s 2024 evaluation.1
FDA statusNot FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA places it in category 2 of its compounding list, for substances that may present significant safety risks.1,4
Human evidenceSmall, short research studies, mostly of single or brief exposures, in about 300 people in total, according to FDA’s evaluation.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is kisspeptin-10?

Kisspeptin-10 is a synthetic peptide of ten amino acids. FDA reports that kisspeptin was first described in 2001 and kisspeptin-10 in 2004.1

FDA reports that clinics most often promote kisspeptin products for weight loss and fertility, and that some compounding pharmacies reported preparing it.1

How is kisspeptin-10 thought to work?

FDA’s evaluation states that kisspeptin-10 binds and activates GPR54, the kisspeptin receptor, which is concentrated in the hypothalamus and also found in the pituitary, placenta and pancreas.1

FDA notes that in animal studies the response can fade with continuous exposure, leaving the peptide inactive, and that laboratory findings suggesting it may promote hardening of the arteries are of unclear clinical relevance.1

What do human studies show?

FDA identified several small studies that together exposed about 300 people, a figure it says may be an overestimate, mostly to single or brief exposures.1

FDA reports that no serious adverse events were described, but that the studies were short, small and often did not report adverse events, and that no published trial tested it on a fixed schedule for more than one day.1

FDA concluded that no meaningful conclusions on effectiveness in men with secondary hypogonadism can be drawn from these studies.1

What the evidence base contains

  • Small, short, or incompletely reported human study Small, short studies in about 300 people, including healthy adults, people with hypogonadotropic hypogonadism and men with type 2 diabetes and low testosterone, which FDA found too small and exploratory to show effectiveness.1
  • Animal or laboratory research Laboratory and animal studies of its effects on reproductive hormones, including loss of response with continuous exposure and effects that may promote hardening of the arteries, described in FDA’s evaluation.1

Evidence-strength label: Limited human data. How this label is assigned

Is kisspeptin-10 FDA-approved?

No. FDA’s evaluation, dated July 5, 2024, states that kisspeptin-10 is not a component of an FDA-approved drug and has no United States Pharmacopeia monograph, and that no product containing it is approved in any country.1

None of the sources reviewed here reports an approval of kisspeptin-10 by FDA.1,4

FDA staff evaluated it for the 503A bulks list, the list of substances pharmacies may use in compounding, for secondary hypogonadism in men, and concluded that the balance of criteria weighs against adding it.1

A Federal Register notice announced the October 29, 2024 advisory-committee meeting that discussed kisspeptin-10. According to the minutes, all 11 voting members voted against placing it on the list.2,3

FDA’s compounding safety-risk page, current as of April 22, 2026, lists kisspeptin-10 in category 2 under the 503A interim policy since September 29, 2023, citing possible immune reactions and limited safety information.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Kisspeptin-10 is not among them.5,6

Timeline

  1. Kisspeptin-10 is first described in the scientific literature, according to FDA’s evaluation.1
  2. FDA places kisspeptin-10 in category 2 under its 503A interim compounding policy, according to its safety-risk page.4
  3. FDA staff date their evaluation recommending against adding kisspeptin-10 to the 503A bulks list.1
  4. A Federal Register notice announces the October 29, 2024 advisory-committee meeting that will discuss kisspeptin-10.3
  5. FDA’s Pharmacy Compounding Advisory Committee votes 11 to 0 against placing kisspeptin-10 on the list.2

What is still unknown?

Whether it helps any condition: FDA found insufficient evidence on effectiveness and no studies by the routes proposed for compounding in men with hypogonadism.1

Its safety with repeated use over weeks or months, which FDA says no published trial has assessed.1

FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 15, 2026.1,4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Kisspeptin-10: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Kisspeptin-10 are a bounded selection, not every registration or paper about Kisspeptin-10. For the years before Kisspeptin-10 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Kisspeptin-10 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Kisspeptin-10 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; on FDA’s compounding safety-risk list (category 2). FDA staff recommended in 2024 against adding kisspeptin-10 to the 503A compounding list, and FDA places it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Kisspeptin-10?

Not FDA-approved; on FDA’s compounding safety-risk list (category 2). FDA staff recommended in 2024 against adding kisspeptin-10 to the 503A compounding list, and FDA places it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
7
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Structural basis for Kisspeptin-10 selectivity toward KISS1R: computational insights.↗Source date November 12, 2026
  2. Literature metadata · added November 15, 2026

    Maternal Kisspeptin-10 Treatment Partially Rescues Fetal and Postnatal Cardiac Programming Disrupted by Maternal Hypothyroidism.↗Source date October 16, 2026
  3. Literature metadata · added November 15, 2026

    Kisspeptin-10 Preserves the Blood-Brain Barrier's Integrity Post-Stroke by Augmenting Claudin-10 Expression.↗Source date June 28, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Kisspeptin-10?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

14Selected dated records
20Connected citations
7Populated source years2017–2026
2/4Record lanes present

Registered human studies

Trial composition

1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.

PhasesPhase 3 1
Status at observationCompleted 1

PubMed bibliography

Publication composition

13 of 13 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 13Research Support, Non-U.S. Gov't 6Comparative Study 1Evaluation Study 1Research Support, N.I.H., Extramural 1Research Support, N.I.H., Intramural 1Validation Study 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
14

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 14 dated records

Research hub

Explore the Kisspeptin-10 evidence record

Open all 14 records →
14Dated records
2Evidence types
14Cited public sources
7Source years

Change ledger

Recently changed for Kisspeptin-10

Open all 14 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT03771326

PeptideScanner retained ClinicalTrials.gov record NCT03771326 at 2026-11-15T22:12:06.897Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was kisspeptin-10.

PeptideScanner change date
November 15, 2026
Cited source date
December 12, 2018
Evidence lane
Clinical trials
Record added

Kisspeptin-10 facilitates a plasma membrane-driven calcium oscillator in gonadotropin-releasing hormone-1 neurons.

PubMed lists PMID 18948403 in Endocrinology as Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2008-10-23 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2018
Evidence lane
Literature metadata
Record added

A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10.

PubMed lists PMID 19934405 in American journal of physiology. Endocrinology and metabolism as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-11-24 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 15, 2026
Cited source date
May 29, 2025
Evidence lane
Literature metadata

Official-source collections

Source records for Kisspeptin-10

Open the full research atlas →
PubMed13

13 with attributed title, venue, publication-date, and type metadata.

  1. Maternal Kisspeptin-10 Treatment Partially Rescues Fetal and Postnatal Cardiac Programming Disrupted by Maternal Hypothyroidism.Cardiovascular toxicology · 2026 09 11
  2. Structural basis for Kisspeptin-10 selectivity toward KISS1R: computational insights.In silico pharmacology · 2026 09 06
  3. Kisspeptin-10 Preserves the Blood-Brain Barrier's Integrity Post-Stroke by Augmenting Claudin-10 Expression.Clinical and experimental pharmacology & physiology · 2025 Nov
Explore all selected literature →

Evidence types

Coverage by source year

Selected records span September 21, 2017 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 14

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Structural basis for Kisspeptin-10 selectivity toward KISS1R: computational insights.↗

    PubMed lists PMID 42707558 in In silico pharmacology as Journal Article, with publication-date metadata of 2026-09-06 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Maternal Kisspeptin-10 Treatment Partially Rescues Fetal and Postnatal Cardiac Programming Disrupted by Maternal Hypothyroidism.↗

    PubMed lists PMID 42726152 in Cardiovascular toxicology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-11 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Kisspeptin-10 Preserves the Blood-Brain Barrier's Integrity Post-Stroke by Augmenting Claudin-10 Expression.↗

    PubMed lists PMID 41022671 in Clinical and experimental pharmacology & physiology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-11 (month precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10.↗

    PubMed lists PMID 19934405 in American journal of physiology. Endocrinology and metabolism as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-11-24 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats.↗

    PubMed lists PMID 23524040 in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences as Journal Article, Research Support, N.I.H., Extramural, Validation Study, with publication-date metadata of 2013-03-04 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Influence of neurokinin B, dynorphin A and kisspeptin-10 on in vitro gonadotropin secretion by anterior pituitary cells isolated from pubescent ewes.↗

    PubMed lists PMID 40144066 in Journal of veterinary research as Journal Article, with publication-date metadata of 2025-01-31 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Immature rat seminal vesicles show histomorphological and ultrastructural alterations following treatment with kisspeptin-10.↗

    PubMed lists PMID 22404961 in Reproductive biology and endocrinology : RB&E as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-03-10 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Provocative tests with Kisspeptin-10 and GnRH set the scene for determining social status and environmental impacts on reproductive capacity in male African lions (Panthera leo).↗

    PubMed lists PMID 36150474 in General and comparative endocrinology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-09-20 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea.↗

    PubMed lists PMID 29264460 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2017-10-16 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Maternal plasma kisspeptin-10 level in preeclamptic pregnant women and its relation in changing their reproductive hormones.↗

    PubMed lists PMID 32045961 in The journal of obstetrics and gynaecology research as Evaluation Study, Journal Article, with publication-date metadata of 2020-02-11 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT03771326↗

    PeptideScanner retained ClinicalTrials.gov record NCT03771326 at 2026-11-15T22:12:06.897Z. Its registry update date was 2018-12-12, and PeptideScanner's reviewed identity mapping was kisspeptin-10.↗

  12. Literature metadata

    Kisspeptin-10 facilitates a plasma membrane-driven calcium oscillator in gonadotropin-releasing hormone-1 neurons.↗

    PubMed lists PMID 18948403 in Endocrinology as Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2008-10-23 (day precision). PeptideScanner associated the retained record with the identity slug kisspeptin-10. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  2. 2
    October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026